As antimicrobial resistance continues to pose a growing global public health challenge, the rational use of antibiotics has become a cornerstone of infectious disease management. In the past, it was widely believed that "using multiple antibiotics together leads to better outcomes." However, modern evidence-based medicine and the principles of Antimicrobial Stewardship (AMS) have demonstrated that not all infections require combination therapy. Inappropriate antibiotic combinations may fail to improve efficacy while increasing the risk of adverse drug reactions, promoting antimicrobial resistance, and raising healthcare costs.
Current domestic and international infectious disease guidelines consistently emphasize that combination antibiotic therapy should only be used when there are clear clinical indications. Treatment decisions should be individualized based on the type of infection, likely pathogens, patient comorbidities, and disease severity. For most common infections, appropriate monotherapy is sufficient to achieve favorable clinical outcomes, whereas combination therapy is generally reserved for specific clinical scenarios.
Why Do Modern Guidelines Increasingly Emphasize Rational Combination Therapy?
The primary goal of antibiotic therapy is not only to eliminate infection but also to maximize treatment efficacy while minimizing antimicrobial resistance and drug-related toxicity.
Historically, combination therapy was often adopted to broaden antimicrobial coverage and increase the likelihood of targeting potential pathogens. However, advances in microbiological testing, antimicrobial susceptibility testing, and rapid molecular diagnostics now enable clinicians to identify causative organisms more quickly. This allows physicians to select targeted antimicrobial therapy rather than relying on prolonged empirical broad-spectrum combination regimens.
In recent years, organizations such as the World Health Organization (WHO), the Infectious Diseases Society of America (IDSA), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have consistently advocated the principle of "empirical therapy followed by targeted de-escalation." Once microbiological results become available, antibiotic therapy should be narrowed promptly to minimize unnecessary exposure to multiple agents.
Consequently, modern antimicrobial stewardship has shifted from the philosophy of "broader coverage is safer" toward "precision therapy, appropriate treatment duration, and minimized antibiotic exposure."
When Is Combination Antibiotic Therapy Clearly Indicated?
Combination therapy is not inherently superior to monotherapy. Its benefits are limited to well-defined clinical situations where it provides clear therapeutic advantages.
For critically ill patients—including those with septic shock, severe sepsis, or rapidly progressing life-threatening infections—empirical combination therapy before pathogen identification can improve initial antimicrobial coverage and increase the likelihood of administering effective treatment early. Once culture and susceptibility results become available, therapy should be promptly adjusted based on microbiological findings.
Combination therapy is also appropriate when infections are likely caused by multiple pathogens. Conditions such as intra-abdominal infections, diabetic foot infections, and complicated pelvic infections often involve mixtures of aerobic bacteria, anaerobic bacteria, Gram-positive organisms, and Gram-negative organisms, making single-agent therapy insufficient to provide comprehensive coverage.
For certain specific pathogens, combination therapy represents the established standard of care. Tuberculosis requires multidrug therapy to reduce the emergence of resistance. Similarly, some nontuberculous mycobacterial infections, selected invasive fungal infections, and Helicobacter pylori eradication regimens all rely on standardized multidrug treatment protocols.
In selected situations, combining antibiotics with different mechanisms of action may produce synergistic bactericidal effects, enhancing antimicrobial activity. However, such strategies should always be supported by robust clinical evidence rather than empirical addition of multiple antibiotics.
What Are the Potential Benefits of Combination Therapy?
When used appropriately, combination antibiotic therapy can improve infection control in carefully selected patients. Its advantages are confined to specific clinical settings rather than routine infections.
One important benefit is broader empirical antimicrobial coverage during the early management of severe infections. Studies have shown that timely administration of effective initial antibiotic therapy is strongly associated with lower mortality among critically ill patients.
For polymicrobial infections, different antibiotics may target different pathogens simultaneously, resulting in more comprehensive infection control. In certain infections, combination regimens may also reduce the likelihood of resistance developing during treatment, helping preserve antimicrobial effectiveness.
Additionally, some carefully selected combinations exploit complementary mechanisms of action to achieve synergistic antibacterial activity, improving bacterial eradication and potentially enhancing clinical outcomes in difficult-to-treat infections.
Nevertheless, these advantages depend on appropriate patient selection, rational regimen design, and evidence-based decision-making. They should not be interpreted as evidence that combination therapy is universally superior to monotherapy.
What Are the Risks Associated with Combination Antibiotic Therapy?
Although combination therapy offers potential benefits, it also carries significant risks. Therefore, modern guidelines consistently emphasize strict adherence to appropriate indications.
First, combining multiple antibiotics increases the likelihood of adverse drug reactions. As the number of medications increases, so does the risk of hepatotoxicity, nephrotoxicity, gastrointestinal adverse effects, allergic reactions, and hematologic toxicity.
Second, unnecessary combination therapy may further disrupt the body's normal microbiota. Alterations of the intestinal, respiratory, and skin microbiomes can increase susceptibility to opportunistic infections, including antibiotic-associated complications such as Clostridioides difficile infection.
Furthermore, prolonged use of broad-spectrum combination regimens may exert greater selective pressure on bacteria, accelerating the emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and even pan-drug-resistant (PDR) organisms, thereby making future treatment considerably more difficult.
In addition, multiple-drug regimens increase the risk of drug-drug interactions, complicate treatment, increase healthcare costs, and may reduce patient adherence. Consequently, combination therapy should always follow the principles of necessity, rationality, and the shortest effective treatment duration.
Combination Therapy Does Not Mean the Entire Treatment Course Must Remain Combined
Modern infectious disease management emphasizes continuous reassessment rather than maintaining a fixed regimen throughout treatment.
For most patients, combination therapy is primarily used during the initial phase of treatment, particularly before the causative pathogen has been identified or when severe infection is suspected. As microbiological culture results, antimicrobial susceptibility data, and clinical responses become available, clinicians should reassess the antimicrobial regimen.
Once the responsible pathogen has been identified and is adequately covered by a single antibiotic, current guidelines recommend timely de-escalation therapy, reducing the number of antibiotics used. Treatment duration should also be individualized according to the infection site, pathogen characteristics, and patient recovery.
This dynamic approach helps reduce antimicrobial resistance, minimizes drug toxicity, and improves overall treatment quality, making it a fundamental component of contemporary antimicrobial stewardship.
How Can Combination Antibiotic Therapy Be Used Scientifically and Appropriately?
Appropriate combination antibiotic therapy should always be based on accurate infection diagnosis, microbiological evidence, and evidence-based clinical practice rather than empirical addition of multiple antibiotics.
Modern guidelines recommend obtaining appropriate microbiological specimens before initiating antimicrobial therapy whenever feasible. Initial empirical treatment should consider the infection site, local epidemiology, previous antimicrobial resistance history, and the patient's underlying medical conditions. During treatment, clinicians should closely monitor clinical response, laboratory findings, and drug safety while optimizing therapy promptly according to culture and susceptibility results.
At the institutional level, antimicrobial stewardship programs—including antibiotic classification systems, multidisciplinary infectious disease consultations, and active pharmacist participation—can further improve the appropriateness of combination therapy while minimizing unnecessary antibiotic exposure.
Conclusion
As evidence-based medicine continues to evolve, antibiotic therapy has shifted from emphasizing "covering as many pathogens as possible" toward precision diagnosis, rational combination therapy, dynamic treatment adjustment, and appropriate treatment duration. Combination therapy is not inherently better simply because more antibiotics are used; rather, it should be reserved for carefully selected clinical indications to maximize therapeutic benefit while minimizing antimicrobial resistance and drug-related toxicity.
For healthcare institutions, strengthening antimicrobial stewardship is essential not only for improving individual patient outcomes but also for protecting public health and supporting long-term antimicrobial resistance control. As a professional platform dedicated to global innovative medicines, infectious disease treatment, and international pharmaceutical services, DengYueMed, a China-based pharmaceutical wholesaler, continues to monitor international infectious disease treatment guidelines, advances in antimicrobial drug development, and global antimicrobial resistance trends. Through professional pharmaceutical information, international drug intelligence, and updates on emerging therapies, DengYueMed supports healthcare institutions, industry partners, and patients in promoting the more scientific, standardized, and responsible use of antimicrobial agents worldwide.